1e
19
1
49
2
2
18
1b
1d
18
30
56
1d
2 29
1d
25
Anil K. Rustgi, MD
78
56
Emeritus Professor of Medicine (Gastroenterology)
28
92
3
5f
Chief, Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine
a5
Director, Digestive Diseases and Liver Clinical Center, University of Pennsylvania Perelman School of Medicine
a1
Member, Cancer Center, Center for Cancer Pharmacology, Chemoprevention Program, University of Pennsylvania
b9
Director, NIH Center for Molecular Studies in Digestive and Liver Diseases, University of Pennsylvania Perelman School of Medicine
90
Director, NIDDK Year Out Program for medical students at Penn, University of Pennsylvania
92
Co-Program Leader, Tumor Biology Program, University of Pennsylvania Abramson Cancer Center
de
Director, Joint Center for Digestive, Liver and Pancreatic Medicine, University of Pennsylvania Perelman School of Medicine and the Children's Hospital of Philadelphia
96
Member, Clinical Trials/Phase I/II Unit, University of Pennsylvania Perelman School of Medicine
b5
Member, Advisory Committee for the Neuroscience of Behavior Initiative, University of Pennsylvania Perelman School of Medicine
11
Department: Medicine
4
1
b
1d
46
Contact information
6c
4
3
3
3
2
4
b
1f
6c
Columbia University Vagelos College of Physicians and Surgeons
34 630 West 168th Street
New York, NY 10032
26
34 630 West 168th Street
New York, NY 10032
35
f
13
Education:
21 7 BS 30 (Molecular Biochemistry & Biophysics) c
37 Yale University, New Haven, CT, 1980.
21 7 MD 15 (Medicine) c
34 Duke University, Durham, NC, 1984.
c
3
3
3
3
8a
Permanent link21 7 BS 30 (Molecular Biochemistry & Biophysics) c
37 Yale University, New Haven, CT, 1980.
21 7 MD 15 (Medicine) c
34 Duke University, Durham, NC, 1984.
c
2 29
21
1e
1d
24
5e
6e
e 7 1d 1f
27
Description of Research Expertise
9b Oncogenes, tumor suppressor genes, tumor microenvironment, tumor metastasis, molecular genetics of GI cancers (colon, pancreatic, upper GI)6e
Description of Other Expertise
27b Our laboratory has had long-standing thematic interests in the cell-type and tissue-type specific actions of certain oncogenes (cyclin D1, EGFR) and tumor suppressor genes (p53, p120 catenin) in modulating the initiation, progression and invasion of gastrointestinal cancers, especially upper GI, pancreatic and colon. To that end, we employ novel three-dimensional cell culture systems (mouse and human origins) and genetically-engineered mouse models to investigate molecular mechanisms. These projects are translated into the objectives of improving molecular diagnostics and experimental therapeutics in patients.e 7 1d 1f